The relationship between patents, pharmaceutical regulation, and the FDA raises bigger questions about who controls medicine. Dr. David Martin argues these systems can protect market exclusivity while sidelining alternatives. His view now challenges viewers to rethink how healthcare innovation is regulated.
Gefällt mir
Kommentar
Teilen
